Everolimus tablets bulk supplier for pharma manufacturers

Everolimus Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 0.75 mg, 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg

Reference Brands: Zortress, Afinitor(US & EU)

Everolimus tablets in transplant and oncology strengths, from 0.75 mg to 10 mg. An mTOR inhibitor listed for hospital pharmacies, importers and tender buyers sourcing specialist prescription medicines.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Everolimus Tablets? List it or send an offer →

Product Description:

Everolimus is an mTOR inhibitor derived from sirolimus. It binds the protein FKBP-12, and that complex blocks mTOR, a kinase that drives cell growth, division and new blood vessel formation. At low doses it is a transplant immunosuppressant; at higher doses, an anticancer agent. The strengths here reflect that split: 0.75 mg belongs to the transplant range, while 2.5 mg, 5 mg, 7.5 mg and 10 mg are oncology strengths. Tablets are swallowed whole with water, not chewed or crushed.

In transplant care it is combined with reduced-dose ciclosporin or tacrolimus and corticosteroids to prevent rejection after kidney, liver or heart transplantation, depending on the label, with dosing guided by trough blood levels. In oncology it is used for hormone receptor-positive, HER2-negative advanced breast cancer with exemestane, neuroendocrine tumours, advanced renal cell carcinoma and tumours linked to tuberous sclerosis complex. Mouth ulcers, pneumonitis, infections, high blood sugar and raised lipids need monitoring. Strong CYP3A4 or P-glycoprotein inhibitors and inducers, and grapefruit, are avoided or managed, as are live vaccines.

Sourcing notes. Say whether you need transplant or oncology strengths, because they sit under different registrations and reference products in many markets, and bioequivalence must be shown against the right one. Everolimus is sensitive to light and moisture, so tablets come in aluminium blisters and stay in the original pack. Ask for zone IVb stability data for hot, humid destinations and a CTD or ACTD dossier. Request the batch CoA, the site GMP certificate and a CoPP. Specify strengths, blister count and target market.

Everolimus Tablets — third party manufacturing & bulk supply

Everolimus Tablets is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Everolimus Tablets is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Everolimus Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Everolimus Tablets →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Everolimus tablets is listed as Tablet in 0.75 mg, 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Everolimus tablets is referenced against Zortress, Afinitor(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.